Intellectual Disability Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Intellectual Disability. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Intellectual Disability receives a directional score of 60/100, combining unmet need (65/100), competitive intensity (96/100) and market attractiveness (95/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)

The reproducible record is Patsnap disease ID da424d5a576347ab86672a98bc20f87f and MeSH identifier D008607. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: US Burden of Disorders Affecting the Nervous System US Burden of Disorders Affecting the Nervous SystemFrom the Global Burden of Disease 2021 Study

Parkinson disease had the largest increase from 1990 in age- standardized rates of DALYs (43.5%; 95% UI, 38.3% to 47.5%), YLDs (25.7%; 95% UI, 10.0% to 41.3%), and YLLs (47.5%; 95% UI, 43.8% to 50.7%), while meningitis had the largest declines (DALYs: −75.5%; 95% UI, −76.9% to −74.1%; YLDs: −80.2%; 95% UI, −81.7% to 78.5%; YLLs: −75.2%; 95% UI, −76.7% to −73.7%). Among neurodevelopmental disorders, age-standard- ized DALY rates of attention-deficit/hyperactivity disorder (ADHD) experienced the largest increase from 1990 at 10.4% (95% UI, 0.9% to 20.0%). Age-standardized DALY rates of idiopathic intellectual disability decreased (−13.3%; 95% UI, −20.4% to −9.5%). For metabolic, infectious, congenital, and neonatal con- ditions affecting the nervous system, diabetic neuropathy had Figure 2. Conditions Affecting Nervous System Health by Disability-Adjusted Life-Years (DALYs) in the United States in 2021, by Relative Contribution to Total DALYs There were a total of 16.6 million total DALYs for disorders affecting the nervous system in 2021. A category of aggregated neurological conditions described in Table 1 as “other neurological disorders” is included. Years lived with disability (YLDs) and years of life lost (YLLs) were summed by condition to yield DALYs.

Review source

Epidemiology evidence 2: Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990–2019 Global, regional, and nationalburden and attributable riskfactors of neurologicaldisorders: The Global Burden ofDisease study 1990–2019

In 2019, the incidence and prevalence of idiopathic epilepsy were 2,898.22 (2.098.72, 3.823.38) in thousands and 25,111.11 (19.033.57, 31.433.01) in thousands, respectively, which resulted in 13,077.62 (9.986.73, 16.734.09) thousands DALYs and 114.01(100.18, 129.93) thousands deaths. From 1990 to 2019, both numbers and age-standardized rates of incidence and prevalence increased, despite this trend, age-standardized rates of DALYs and deaths decreased (Table 1). The age-standardized DALY rate showed a strong negative correlation with the [SDIr = −0.68, p < 0.001 (Supplementary Table S3)]. In terms of age, idiopathic epilepsy mainly caused disease burden for the 5–30 years old group (Figure 4). Neural tube defects Neural tube defects caused 7,743.43 (95%UI 5,726.20, 11,022.80) thousands DALYs in 2019, which showed a decreasing trend of 47.1% (95%UI 32.40, 58.29) from 1990 to 2019. Crude numbers and age-standardized rates of incidence and deaths also decreased, but the prevalence increased. The burden on neural tube defects showed distinct regional distribution (Table 1 and Figure 1). It ranked the 15th in Western Europe, but ranked the 5th in Western sub-Saharan Africa (Figure 3). Age-standardized DALY rate showed a strong negative correlation with the SDI (r = −0.83, p < 0.001) (Supplementary Table S3). In terms of age, the disease burden of neural tube defects mainly impacted the early neonatal, post neonatal and 1–4 years old groups (Figure 4). Brain and central nervous system cancer

Review source

Epidemiology evidence 3: Disease burden and government spending on mental, neurological, and substance use disorders, and self-harm: cross-sectional, ecological study of health system response in the Americas

2 GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1603–58. 3 Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005; 352: 2515–23. 4 Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 2009; 18: 23–33. 5 GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–602. 6 Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry 2016; 3: 171–78. 7 Chisholm D, Flisher A, Lund C, et al. Scale up services for mental disorders: a call for action. Lancet 2007; 370: 1241–52. 8 Mnookin S. Out of the shadows: making mental health a grlobal development priority. Washington DC: World Bank Group, World Health Organization, 2016. 9 Global Health Data Exchange. Global Burden of Disease Study 2015 Results Tool. Seattle, WA, United States. http://ghdx.healthdata. org/gbd-results-tool (accessed Jan 1, 2017). 10 WHO. Mental health action gap. Scaling up care for mental, neurological, and substance use disorders. Geneva: World Health

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Intellectual Disability, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Intellectual Disability thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: COL1A1

Type I collagen is a member of group I collagen (fibrillar forming collagen).

The mechanism anchor is COL1A1, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 2420 registered studies.

• NCT07785011 — Effect of Sensory Integration on Gross and Balance on Children With Down Syndrome; Recruiting; Not Applicable; sponsor Cairo University; enrollment 40.
• NCT07778654 — Vestibular Stimulation Versus Foot Intrinsic Muscle Exercises in Children With Down Syndrome (VESTIB-FIME); Not yet recruiting; Not Applicable; sponsor Shalamar Hospital; enrollment 48.
• NCT07779512 — Infant Safe Sleep in Pediatric Emergency Depratment; Not yet recruiting; Not Applicable; sponsor State University of New York at Buffalo; enrollment 214.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

The query returned 8 directly matched 2023–2026 transactions.

• QurAlis Announces Exclusive License on Novel Mechanism for Fragile X Syndrome (FXS) to Enable Development of First Potential Disease-Modifying Therapy (2025-05-15). Review stage, rights, territory, milestones and economics before using it as a comparable.
• Apertura Gene Therapy and Rett Syndrome Research Trust Collaborate to Pioneer Advanced Genetic Medicines for Rett Syndrome Using TfR1-Targeted AAV Capsid (2025-04-30). Review stage, rights, territory, milestones and economics before using it as a comparable.
• JCR Pharmaceuticals Regains Full Commercialization Rights to JR-141 (2024-06-25). Review stage, rights, territory, milestones and economics before using it as a comparable.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate COL1A1 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Intellectual Disability merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Intellectual Disability is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.